Image of an eye
Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

PYC Therapeutics Ltd (ASX:PYC) has announced that the US Food and Drug Administration (FDA) has granted ‘Rare Pediatric Disease (RPD)’ designation to its development program for a drug aimed at treating patients with blinding eye disease Autosomal Dominant Optic Atrophy (ADOA).

Earlier this month, PYC said it had received regulatory approval to begin human trials for the drug – PYC-001 – involving individuals with ADOA, with a Phase 1 Single Ascending Dose study to begin imminently.

ADOA – which affects 1 one every 35,000 people – is a condition which begins in childhood and ultimately leads to legal blindness by middle age among most patients, being caused by insufficient expression of the OPA1 gene in the retina.

Additionally, there are no current treatment options for patients with ADOA, although the market to address this condition is estimated at more than $2 billion per year.

The designation received by the FDA is focused on treatments of OPA1-associated
vision loss, and its Rare Pediatric Disease program aims to incentivise drug development for serious and rare diseases affecting children.

Receiving this status means that PYC will be eligible to receive a Priority Review Voucher (PRV) which can be redeemed to receive priority review for a different product or sold to another sponsor.

PYC shares have risen on the news. At 12:34 AEST, they were trading at 13.5 cents: a rise of 3.85% since the market opened.

PYC by the numbers
More From The Market Online
Organised crime concept

Panic, paranoia, and gangland politics: HotCopper users react to Dubber’s missing $26M

HotCopper users have reacted to overnight reports Dubber has seen $26M disappear from its coffers due…
Market Update Graphic

ASX Market Update: Bourse nears record approaching week’s end | November 22, 2024

The bourse is near record territory to close out the week on the back of a…
Image of eyes in closeup

Scientific conference spotlights PYC’s work on blindness disease treatment

PYC Therapeutics Ltd will have data from its ongoing trial into a drug candidate to treat…
A man with a copper nugget in his hands

IP anomaly thrills Cannindah with project extension hopes in QLD

Cannidah Resources has carried out geophysical work at its flagship project in Queensland which highlighted an…